

Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2017

Sales of Major Products

Supplemental Data

For information purpose only

		Hundreds of Millions of yen					
		Year ended March 31, 2017			Year ending March 31, 2018		
		Results	Increase/Decrease		Forecast	Increase/Decrease	
Opdivo	Agent for treatment of unresectable melanoma, unresectable, advanced or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical hodgkin lymphoma, and recurrent or metastatic head and neck cancer	¥ 1,039	¥ +828	+391.3 %	¥ 740	¥ Δ 299	Δ 28.8 %
Glactiv	Agent for type II diabetes	294	Δ 20	Δ 6.5 %	295	+1	+0.4 %
Orencia SC	Agent for rheumatoid arthritis	116	+36	+44.5 %	145	+29	+25.2 %
Opalmon	Circulatory system agent	170	Δ 57	Δ 25.0 %	140	Δ 30	Δ 17.8 %
Recalbon	Agent for osteoporosis	113	Δ 0	Δ 0.0 %	110	Δ 3	Δ 2.6 %
Forxiga	Agent for type II diabetes	78	+35	+82.6 %	100	+22	+28.1 %
Rivastach	Agent for Alzheimer's disease	89	+10	+13.1 %	100	+11	+12.9 %
Emend/Proemend	Agent for Chemotherapy-induced nausea and vomiting	99	+4	+4.3 %	100	+1	+1.2 %
Kyprolis	Agent for relapsed or refractory multiple myeloma	20	Launched in August 2016		60	+40	+206.1 %
Onoact	Agent for tachyarrhythmia during and post operation	57	0	+0.3 %	60	+3	+4.8 %
Onon	Agent for bronchial asthma and allergic rhinitis	68	Δ 22	Δ 24.2 %	55	Δ 13	Δ 19.0 %
Staybla	Agent for overactive bladder (pollakiuria and urinary incontinence)	48	Δ 4	Δ 7.6 %	45	Δ 3	Δ 5.7 %
Parsabiv	Agent for secondary hyperparathyroidism	2	Launched in February 2017		30	+28	+1439.8 %
Onon dry syrup	Agent for pediatric bronchial asthma and allergic rhinitis	41	Δ 15	Δ 26.7 %	30	Δ 11	Δ 26.9 %
Foipan	Agent for chronic pancreatitis and postoperative reflux esophagitis	38	Δ 13	Δ 25.7 %	30	Δ 8	Δ 21.7 %
Kinedak	Agent for diabetic peripheral neuropathy	29	Δ 12	Δ 29.5 %	25	Δ 4	Δ 13.2 %

Note: Sales of products are shown in a gross sales basis.